Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Assets (2016 - 2025)

Ocular Therapeutix has reported Assets over the past 13 years, most recently at $808.1 million for Q4 2025.

  • Quarterly results put Assets at $808.1 million for Q4 2025, up 76.46% from a year ago — trailing twelve months through Dec 2025 was $808.1 million (up 76.46% YoY), and the annual figure for FY2025 was $808.1 million, up 76.46%.
  • Assets for Q4 2025 was $808.1 million at Ocular Therapeutix, up from $410.9 million in the prior quarter.
  • Over the last five years, Assets for OCUL hit a ceiling of $808.1 million in Q4 2025 and a floor of $122.6 million in Q2 2023.
  • Median Assets over the past 5 years was $236.9 million (2021), compared with a mean of $315.6 million.
  • Biggest five-year swings in Assets: tumbled 31.47% in 2023 and later surged 321.92% in 2024.
  • Ocular Therapeutix's Assets stood at $204.9 million in 2021, then dropped by 27.14% to $149.3 million in 2022, then skyrocketed by 68.84% to $252.1 million in 2023, then soared by 81.68% to $457.9 million in 2024, then surged by 76.46% to $808.1 million in 2025.
  • The last three reported values for Assets were $808.1 million (Q4 2025), $410.9 million (Q3 2025), and $451.3 million (Q2 2025) per Business Quant data.